^
    6d
    A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=63, Recruiting, BeOne Medicines | N=44 --> 63
    Enrollment change • First-in-human
    |
    MTAP (Methylthioadenosine Phosphorylase)
    13d
    A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) (clinicaltrials.gov)
    P2, N=260, Not yet recruiting, Bristol-Myers Squibb
    New P2 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    Opdivo (nivolumab) • carboplatin • gemcitabine • temozolomide • albumin-bound paclitaxel • pemetrexed • navlimetostat (BMS‐986504) • Opdualag (nivolumab/relatlimab-rmbw) • daraxonrasib (RMC-6236) • pumitamig (BNT327)
    1m
    A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended
    Trial suspension
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • navlimetostat (BMS‐986504)
    1m
    Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (clinicaltrials.gov)
    P1, N=36, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2026 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Lynparza (olaparib) • navlimetostat (BMS‐986504)
    2ms
    CA240-0029: A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer with Homozygous MTAP Deletion (2025-521511-40-00)
    P2/3, N=191, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • navlimetostat (BMS‐986504)
    2ms
    A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors (2025-520623-24-00)
    P1/2, N=195, Recruiting, Bayer AG
    New P1/2 trial • First-in-human
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    2ms
    CA240-0030: A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygous MTAP deletion (2025-522598-12-00)
    P2/3, N=162, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • navlimetostat (BMS‐986504)
    2ms
    A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=40, Recruiting, PharmaEngine | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    2ms
    Preclinical Evaluation of 68Ga-Labeled GSK3326595 for PRMT5 Expression with microPET-CT in Pan-Cancer. (PubMed, Mol Pharm)
    This research demonstrates that [68Ga]Ga-DOTA-FZ-P5R enables rapid imaging of PRMT5-positive tumors. The probe has significant potential to enable individualized and precise diagnosis in patients with PRMT5-positive tumors, define an optimal treatment window, assess therapeutic efficacy, and serve as a predictive imaging modality for tumor resistance.
    Preclinical • Journal • Pan tumor
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    pemrametostat (GSK3326595)
    2ms
    Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    Lynparza (olaparib) • navlimetostat (BMS‐986504)
    2ms
    A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) (clinicaltrials.gov)
    P1/2, N=329, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=649 --> 329
    Enrollment closed • Enrollment change
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    docetaxel • AMG 193
    3ms
    A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, IDEAYA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    IDE397